filmov
tv
ASCO 2023 Highlights on erdafitinib in metastatic urothelial cancer with select FGFR alterations
Показать описание
Reporting from ASCO 2023, Yohann Loriot discusses the results from the THOR study erdafitinib in patients with advanced or metastatic urothelial cancer with select FGFR alterations.
Abstract: LBA4619 - Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt), presented by Yohann Loriot
Produced by the European Society for Medical Oncology
Abstract: LBA4619 - Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt), presented by Yohann Loriot
Produced by the European Society for Medical Oncology
0:04:47
0:00:55
0:19:14
0:01:04
0:01:47
0:02:47
0:01:47
0:01:27
0:06:20
0:05:25
0:00:18
0:00:27
0:00:55
0:04:51
0:01:49
0:00:55
0:02:12
0:01:15
0:02:20
0:00:52
0:03:26
0:03:37
0:01:47
0:01:34